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NICE versus SIGN on psychosis and 
schizophrenia:  same roots, similar guidelines 
different interpretations  
 
Summary 
A recent editorial claimed that the 2014 NICE guideline on psychosis and schizophrenia, unlike its 
equivalent 2013 SIGN guideline, is biased towards psychosocial treatments and against drug 
treatments. In this article we underline that the NICE and SIGN guidelines recommend similar 
interventions, but that the NICE guideline has   more rigorous methodology. Our analysis suggests 
that the authors of the editorial appear to have succumbed to bias themselves. 
[word count:  66] 
 
Introduction 
In May 2015, Mark Taylor, co-chair of the Scottish Intercollegiate Guidelines Network (SIGN) 
guideline on schizophrenia published in 2013 (referred to hereafter as ‘SIGN131’) (Scottish 
Intercollegiate Guidelines Network, 2013), wrote an editorial for this journal (co-authored by 
Udayanga Perera) claiming that the National Institute for Health and Care Excellence (NICE) 
guideline on Psychosis and Schizophrenia (National Institute for Health and Care Excellence, 2014) 
(referred to hereafter as ‘CG178’) was open to a critique of bias, while SIGN131 was unbiased and 
evidence-based. They claimed that CG178 showed positive bias to psychosocial interventions, in 
particular cognitive behavioural therapy for psychosis (CBTp) and arts therapies, and showed 
negative bias to drug treatment.  
 
Given the status that evidence-based guidelines in mental health now have in psychiatric practice, it 
is important to understand how one set of evidence can lead two guideline developers to two 
seemingly divergent views. It is important, and not mentioned in Taylor and Perera’s editorial, that 
both SIGN131 and CG178 are updates of the 2009 NICE guideline on schizophrenia  (referred to here 
as ‘CG82’ (National Institute for Clinical Excellence, 2009). We will describe the institutions, 
processes and methodologies used for developing the NICE and SIGN guidelines, and then examine  
the claims made by the co-chair of SIGN131 about CG178. 
 
NICE guideline production and the National Collaborating Centres 
 
NICE began providing evidence-based guidance for the NHS in England in 1999 and has rapidly 
become one of the most important innovation in health and social care. The clinical guidelines 
programme is run by the National Collaborating Centres (NCCs), including the National Collaborating 
Centre for Mental Health (NCCMH) which produced the very first NICE guideline (on schizophrenia) 
in 2002. The World Health Organisation (WHO) evaluated this as the world’s best evidence-based 
guideline on schizophrenia, compared with 25 other national guidelines (Gaebel, Weinmann, 
Sartorius et al, 2005). The NCCMH has updated the original NICE guideline on schizophrenia twice ( 
2009 and 2014). 
 
Methodology, quality assurance and conflicts of interest 
 
Each NICE guideline takes just over 2 years to produce by a Guideline Development Group (GDG), 
consisting of about 15 experts recruited through public advert, including researchers, professionals, 
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service users and carers, supported by a technical team, including systematic reviewers, health 
economists, information scientists, project managers and research assistants. The GDG is an 
independent advisory committee that strictly follows NICE’s published methodology (CG178 used 
the 2012 version of the guidelines manual (National Institute for Health and Care Excellence, 2012)) 
1. All processes and products are continuously monitored and quality assured by NICE’s own 
commissioning managers, editors and technical support unit, and subjected to several stages of 
validation (including being critiqued by extensive stakeholder and external expert consultation and 
evaluation). 
 
NICE takes the issue of conflicts of interest very seriously because of the potential threat to the 
integrity and transparency of the guidelines, and has a well-defined process for recording any 
interests and dealing with conflicts. If there are conflicts of interest related to certain topics a GDG 
member would be asked to leave the GDG meeting for the period of time that the topic of interest 
was being discussed. If a GDG member discloses an interest that significantly conflicts with their role 
as a GDG member they would be asked to leave the GDG entirely. Declarations of interest are 
included in the final guideline, and are in the public domain during the consultation of the guideline. 
Finally, and an important difference between NICE 2014 and SIGN 2013, is that a person cannot be 
appointed as a NICE guideline chair if they have a personal pecuniary conflict of interest. This 
appears not to be the case for SIGN 2013. 
 
NICE and SIGN on schizophrenia: different scopes and different methods 
 
For NICE CG178, the evidence reviews for pharmacological and psychological interventions was not 
updated since NICE’s view (based on literature surveillance and expert consultation, including 
psychopharmacology experts) was that there had been insufficient new evidence since the 
publication of CG82 in 2009. Instead, NICE asked the NCCMH to expand the areas within the 
guideline to include self-management, carer experience, carer interventions and peer support, and 
to update service level interventions such as early intervention and assertive community treatment, 
areas that did have new evidence that might change guideline recommendations. Most of the 
reviews undertaken were new reviews conducted by the NCCMH guided by the GDG. All processes 
and methods were subject to the usual, extensive quality assurance, expert review and stakeholder 
consultation. Furthermore, in addition to making available the full guideline and appendices, NICE 
publishes minutes of the GDG meetings and documents from both consultations (scope and draft 
recommendations)2. As far as we can tell, none of this detailed information underpinning guideline 
development is publically available for SIGN guidelines. 
 
For SIGN131, the scope was extended to include psychosis with coexisting substance misuse and 
perinatal issues (for both of these areas, NICE has whole guidelines3). SIGN131 was largely based on 
CG82 and undertook a narrative synthesis of RCTs and other studies published between 2008 and 
2011. The additional syntheses were undertaken by SIGN reviewers in conjunction with their GDG. 
The guideline did not undertake any de novo meta-analyses or update meta-analyses from CG82. 
SIGN131 underwent consultation and peer review, but documents from this process are not made 
routinely available.  
 
NICE and SIGN: how are they different? 
                                                 
1 In October 2014, there was a major revision of the manual, which unified methodologies across all 
NICE programmes: 
https://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20overview. 
2 https://www.nice.org.uk/guidance/cg178/documents 
3 http://www.nice.org.uk/guidance/cg120; http://www.nice.org.uk/guidance/cg192 
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The NICE and SIGN guidelines have a number of similarities, for example recommending the use of 
antipsychotics (including clozapine), family intervention, early interventions, assertive community 
treatment and CBTp. However, there are also many differences, ones which Taylor and Perera bring 
to the fore. We will deal with these in turn. 
 
Psychosis and schizophrenia versus schizophrenia 
Taylor and Perera criticise CG178 for including the term psychosis in the title as potentially 
ambiguous. The title change from ‘schizophrenia’ to ‘psychosis and schizophrenia’ came about 
through consultation with service users and professional groups who expressed the view that the 
guideline should update early intervention in psychosis services, which include people with ‘early 
psychosis’. It therefore made sense that the title reflected the content. The recent Schizophrenia 
Commission (independent of NICE) recommended exercising ’extreme caution in making a diagnosis 
of schizophrenia as it can generate stigma and unwarranted pessimism’ and suggest ‘the more 
general term “psychosis” is preferable, at least in the early stages’4. 
 
Psychological versus pharmacological interventions 
Taylor and Perera also suggest that, on a simple count of recommendations on psychological and 
pharmacological interventions, they have discovered bias in the NICE guideline. They assert that 
SIGN131 is less biased because 60% of all its recommendations refer directly to drug treatments, 
whereas a mere 24% of recommendations in CG178 refer to drugs and most of those are in 
combination with psychosocial interventions. Given the very different scopes and total 
recommendations of the two guidelines, this assertion is meaningless.  For the record, CG178 
includes 110 recommendations of which 24 (22%) are about psychological treatment and 31 (28%) 
are about antipsychotic medication. Only four recommendations are about both psychological and 
antipsychotic treatment. Counting recommendations on drugs and on psychological treatments has 
no grounding in evidence. The suggestion that these percentages mean that CG178 is biased against 
drug treatments and in favour of CBTp is, in our view, unfounded. 
 
CBT as a panacea 
Taylor and Perera also imply that CBTp is presented as a panacea. Certainly CG178 recommends that 
everyone with psychosis or schizophrenia should be offered CBTp on the basis of the systematic 
review and meta-analysis from 2009. The suggestion that a more recent, less favourable review 
(Jauhar et al., 2014) would have altered this recommendation ignores the fact that there were 
another 4 reviews of CBTp published last year (Burns, Erickson, & Brenner, 2014; Turner, Gaag, 
Karyotaki, & Cuijpers, 2014; Mark van der Gaag, Valmaggia, & Smit, 2014; Velthorst et al., 2015), and 
4 of the 5 (including (Jauhar et al., 2014)) concluded that there were significant benefits to CBTp 
compared with treatment as usual or active control comparators. Additionally, their cited review 
(Jauhar et al., 2014) did not include any consideration of effects at follow-up, had not pre-registered 
their protocol and has been criticised (Peters, 2014) for idiosyncratic inclusion criteria and drawing 
conclusions unjustified by the evidence.  
 
Supposed bias in trials of CBT 
Taylor and Perera also cite the importance of masking in studies of CBTp, with effect sizes being 
lower in blinded trials. Blinding is an acknowledged problem in psychological treatment trials, which 
have the disadvantage that patients will know if they receive the treatment or a comparator. Blind 
assessors will not know however, and more recent CBTp trials include these. These sources of 
potential bias are also accounted for in NICE processes.   While double blind drug treatment trials 
have the apparent advantage that patients do not know if they receive the drug or its comparator, 
                                                 
4 https://www.rethink.org/about-us/the-schizophrenia-commission 
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because side effects such as weight gain or extrapyramidal effects are noticeable, both patients and 
assessors may be able to guess.  These issues are rarely discussed in drug trials.  
 
However, it is unfortunate that Taylor and Perera make no mention of another bias, predominantly 
associated with the drug industry, of selective publication of studies. NICE guidelines have played a 
leading role in reducing the impact of bias across the board, including selective publishing (T.  
Kendall, Glover, Taylor, & Pilling, 2011).The NICE recommendation that CBTp be offered is made on 
the basis that some people respond and others will not, but we are currently unable to identify who 
is likely to benefit at an individual level. This is also the case for antipsychotics.  
 
Taylor and Perera further propose that CBTp may be associated with specific adverse effects; while 
this is a possibility, current evidence, including from the very trials they cite, have shown fewer 
deteriorations (Anthony P. Morrison et al., 2014) and significant improvements in internalised 
stigma (A.P. Morrison et al., 2012) relative to comparators. Finally, in Taylor and Perera’s 
conclusions, they assert that CG178 makes strong recommendations based on no evidence at all, for 
instance that the dose of CBT should be at least 16 planned sessions. This is untrue; justification is 
provided in the relevant section of the full guideline (see 9.4.9)5, and SIGN131 contains the same 
recommendation. 
 
 
CBT for at-risk mental states 
For CG178, a meta-analysis of drug and psychological treatment trials for people thought to be at 
risk of psychosis (at-risk mental states; ARMS) was conducted. SIGN131 did not examine treatments 
for ARMS. ARMS were originally evaluated in the NICE guideline on psychosis and schizophrenia in 
children and young people (CG155; published in January 2013) and it was recommended that CBT 
should be considered as there was evidence of benefit, while treatment with antipsychotics 
appeared to show no benefit. For adults, CG178 strengthened this recommendation to ‘offer CBT’ 
for people with ARMS. This change occurred on the basis of inclusion of an additional trial in the 
meta-analysis that was conducted by the GDG (Stafford, Jackson, Mayo-Wilson, Morrison, & Kendall, 
2013). The conclusion that CBT could prevent transition to psychosis at 12 months in some people 
was also replicated by 2 independent meta-analyses (Hutton & Taylor, 2013; M. van der Gaag et al., 
2013) published in the period between CG155 and CG178.  
 
CBT alone for first episode psychosis 
CG178 states that, in order to promote consistency with CG155, ‘[for people with first episode 
psychosis] the GDG saw the value in advising practitioners of the equivocal evidence regarding 
psychological interventions when compared with antipsychotic medication and recommended that if 
a person wished to try a psychological intervention alone, this could be trialled over the course of 1 
month or less’. A Cochrane review examining the effectiveness of antipsychotics versus placebo or 
psychosocial interventions in early schizophrenia concluded that the data are too sparse to assess 
the outcomes (Bola, Kao, & Soydan, 2012). As Taylor and Perera observe, absence of evidence is not 
evidence of absence of an effect, and we have no evidence to suggest that medication must be the 
first-line intervention for people who retain decision-making capacity. The recommendation to allow 
choice underlines the commitment to shared decision making and collaborative care that is 
emphasised in the NICE service user experience guideline(National Institute for Clinical Excellence, 
2011), and also reflects the inclusion of people with lived experience as core members of the GDG, 
which is a strength rather than a weakness, since guidelines that do not take account of the wider 
context (including human rights issues) could be harmful. Although the guideline group concluded  
that adding an additional delay of one month to the duration of untreated psychosis was highly 
unlikely to have a deleterious effect on long term outcomes, CG178 nevertheless recommends: 
                                                 
5 http://www.nice.org.uk/guidance/cg178/evidence 
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‘advise people who want to try psychological interventions alone that these are more effective when 
delivered in conjunction with antipsychotic medication’. 
 
 
Arts therapies 
NICE CG178 included recommendations from CG82, which were based on a systematic review of a 
range of different psychosocial interventions. Apart from CBTp and family intervention no other 
psychosocial intervention except for arts therapies was recommended in 2009. There were sufficient 
trials to undertake a meta-analysis of arts therapies, including art therapy, music therapy and body-
dance movement therapy. SIGN131 did not undertake any review of arts therapies and yet Taylor 
and Perera criticise CG178 for giving a tentative recommendation for arts therapies in the treatment 
of negative symptoms. CG178 recommends that arts therapies may be considered for negative 
symptoms because early data suggested that arts therapies had an effect where drug treatments 
appear not to for negative symptoms. Moreover, the effect size for arts therapies in targeting 
negative symptoms was slightly larger than for CBT. As the intervention with the largest effect size, 
the GDG was justified in recommending this as a possible treatment. In doing so the GDG also 
increased the treatment options available to people with psychosis and schizophrenia. Updating 
these recommendations was not in the scope of CG178, and the more recent Matisse trial, not 
considered in CG82 is unlikely to change the recommendations (T. Kendall, 2012). 
 
Antipsychotics 
CG178 included recommendations from CG82 for the use of antipsychotic medication, with some 
amendments for clarity and for consistency with CG155. These recommendations were based on 
several systematic reviews covering: a) initial treatment of people with first-episode or early 
schizophrenia, b) oral antipsychotic medication in the treatment of the acute episode, c) promoting 
recovery in people with schizophrenia that is in remission, d) promoting recovery in people with 
schizophrenia whose illness has not responded adequately to treatment, e) treatment with 
depot/long-acting injectable antipsychotic medication, f) side effects of antipsychotic medication, g) 
effectiveness of antipsychotic medication based on pragmatic clinical trials, and h) health economic 
evidence. Taylor and Perera make a number of factually inaccurate claims about these 
recommendations. First, they claim there was an absence of a relevant expert on the GDG, and this 
led to ‘non-specific and vague’ recommendations about antipsychotic pharmacotherapy. However, 
CG82, which developed these recommendations, included several experts in psychopharmacology. 
Second, they state the recommendations do not reflect the evidence that there are efficacy 
differences between antipsychotics. However, as can be seen in section 10.10 of the full guideline, 
the GDG considered this issue. The recommendations reflect their view that treatment with 
antipsychotics should be considered an explicit individual therapeutic trial, with a collaborative 
choice of antipsychotic made by service user and professional together. Third, they claim that 
recommendation 10.11.1.116, which recommends not using a loading dose, illustrates that the 
guideline has ‘overlooked that long-acting injectable paliperidone palmitate requires a loading dose’. 
However, this recommendation is in a section specific to use of oral antipsychotics. In the section on 
using long-acting antipsychotics, it is recommended that prescribers follow the BNF or SPC. Finally, 
they suggest that CG178 does not include recommendations for ‘treatment-resistant schizophrenia 
and negative symptoms’ when these are, in fact, contained in sections 10.5 and 9.3.8.1. In our view, 
these assertions are both careless and irresponsible. 
 
What could explain the differences between the NICE and SIGN guidelines? 
 
                                                 
6 Numbering is based on the full version of CG178. 
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The differences between the two guidelines in scope, methodology and rigour explain most, but not 
all, of the differences between SIGN and NICE on psychosis and schizophrenia. NICE probably does 
undertake a more exacting and reliable approach and has covered much more ground in much 
greater depth in psychosis and schizophrenia than SIGN have to date (NICE have 5 guidelines of 
direct relevance). However, the differences between NICE (CG178) and Taylor and Perera’s views are 
much greater than between the content of NICE (CG178) and SIGN (SIGN131). It is important to 
restate that the NICE (CG178) and the SIGN (SIGN131) guidelines are both based upon the NICE 
guideline of 2009 - CG82 - a fact not even acknowledged in Taylor and Perera’s editorial. Indeed, 
their editorial uses the evidence, and guideline recommendations, selectively, and in so doing 
demonstrates surprisingly limited knowledge of both the 2009 (CG82) and the 2014 (CG178) NICE 
guidelines and the evidence upon which these guidelines have been developed. In misrepresenting 
CG178, Taylor and Perera may themselves be guilty of bias. 
 
In our view, disagreement, analysis and debate are essential aspects of an intellectual culture rooted 
in evidence-based medicine, whereas ill-supported accusations of bias, and going beyond the 
evidence is not. This is why NICE has such rigorous methodologies and structures underpinning the 
production of their guidelines.  
[word count:  2849] 
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